Cytokine release syndrome after radiation therapy: case report and review of the literature

Abstract Background Cytokine release syndrome (CRS) has been reported after immunologic manipulations, most often through therapeutic monoclonal antibodies. To our knowledge, CRS after radiation therapy (RT) for cancer has not been reported before. The development of unusual clinical signs and sympt...

Full description

Bibliographic Details
Main Authors: Christopher A. Barker, Samuel K. Kim, Sadna Budhu, Konstantina Matsoukas, Anthony F. Daniyan, Sandra P. D’Angelo
Format: Article
Language:English
Published: BMJ Publishing Group 2018-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40425-017-0311-9
_version_ 1818882800298754048
author Christopher A. Barker
Samuel K. Kim
Sadna Budhu
Konstantina Matsoukas
Anthony F. Daniyan
Sandra P. D’Angelo
author_facet Christopher A. Barker
Samuel K. Kim
Sadna Budhu
Konstantina Matsoukas
Anthony F. Daniyan
Sandra P. D’Angelo
author_sort Christopher A. Barker
collection DOAJ
description Abstract Background Cytokine release syndrome (CRS) has been reported after immunologic manipulations, most often through therapeutic monoclonal antibodies. To our knowledge, CRS after radiation therapy (RT) for cancer has not been reported before. The development of unusual clinical signs and symptoms after RT led us to investigate the possibility of CRS after RT and review the medical literature on this topic. Case presentation A 65 year-old man with untreated chronic lymphocytic leukemia and recurrent, metastatic Merkel cell carcinoma undergoing anti-programmed death 1 (PD1) immunotherapy was referred for palliative RT to sites of progressing metastases. Within hours of each weekly dose of RT, he experienced fever, tachycardia, hypotension, rash, dyspnea, and rigors. Based on clinical suspicion for CRS, blood cytokine measurements were performed 1 h after the second and third dose of RT and demonstrated tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) levels approximately ten-fold higher than normal. These were near normal immediately prior to the third dose of RT, and resolved to normal levels 3 weeks after RT. He experienced rapid regression of irradiated tumors, with development of new sites of metastases soon thereafter. A literature review revealed no clinical cases of CRS after RT for cancer. Conclusions RT during anti-PD1 immunotherapy in a patient with underlying immune dysfunction appeared to be the putative mediator of an immune process which yielded significant increases in pro-inflammatory cytokines, and produced the clinical symptoms meeting the definition of grade 3 CRS. This case demonstrates the capability of RT to elicit immune-related adverse events.
first_indexed 2024-12-19T15:23:31Z
format Article
id doaj.art-7604780bf8d74b849a5372e8dd2b3ff9
institution Directory Open Access Journal
issn 2051-1426
language English
last_indexed 2024-12-19T15:23:31Z
publishDate 2018-01-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj.art-7604780bf8d74b849a5372e8dd2b3ff92022-12-21T20:15:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262018-01-01611710.1186/s40425-017-0311-9Cytokine release syndrome after radiation therapy: case report and review of the literatureChristopher A. Barker0Samuel K. Kim1Sadna Budhu2Konstantina Matsoukas3Anthony F. Daniyan4Sandra P. D’Angelo5Department of Radiation Oncology, Memorial Sloan Kettering Cancer CenterDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer CenterImmunology, Memorial Sloan Kettering Cancer CenterInformation Systems and Library, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Memorial Sloan Kettering Cancer CenterDepartment of Medicine, Memorial Sloan Kettering Cancer CenterAbstract Background Cytokine release syndrome (CRS) has been reported after immunologic manipulations, most often through therapeutic monoclonal antibodies. To our knowledge, CRS after radiation therapy (RT) for cancer has not been reported before. The development of unusual clinical signs and symptoms after RT led us to investigate the possibility of CRS after RT and review the medical literature on this topic. Case presentation A 65 year-old man with untreated chronic lymphocytic leukemia and recurrent, metastatic Merkel cell carcinoma undergoing anti-programmed death 1 (PD1) immunotherapy was referred for palliative RT to sites of progressing metastases. Within hours of each weekly dose of RT, he experienced fever, tachycardia, hypotension, rash, dyspnea, and rigors. Based on clinical suspicion for CRS, blood cytokine measurements were performed 1 h after the second and third dose of RT and demonstrated tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) levels approximately ten-fold higher than normal. These were near normal immediately prior to the third dose of RT, and resolved to normal levels 3 weeks after RT. He experienced rapid regression of irradiated tumors, with development of new sites of metastases soon thereafter. A literature review revealed no clinical cases of CRS after RT for cancer. Conclusions RT during anti-PD1 immunotherapy in a patient with underlying immune dysfunction appeared to be the putative mediator of an immune process which yielded significant increases in pro-inflammatory cytokines, and produced the clinical symptoms meeting the definition of grade 3 CRS. This case demonstrates the capability of RT to elicit immune-related adverse events.http://link.springer.com/article/10.1186/s40425-017-0311-9Cytokine release syndromeRadiation therapyRadiotherapySystemic inflammatory response syndromeCytokineTumor necrosis factor
spellingShingle Christopher A. Barker
Samuel K. Kim
Sadna Budhu
Konstantina Matsoukas
Anthony F. Daniyan
Sandra P. D’Angelo
Cytokine release syndrome after radiation therapy: case report and review of the literature
Journal for ImmunoTherapy of Cancer
Cytokine release syndrome
Radiation therapy
Radiotherapy
Systemic inflammatory response syndrome
Cytokine
Tumor necrosis factor
title Cytokine release syndrome after radiation therapy: case report and review of the literature
title_full Cytokine release syndrome after radiation therapy: case report and review of the literature
title_fullStr Cytokine release syndrome after radiation therapy: case report and review of the literature
title_full_unstemmed Cytokine release syndrome after radiation therapy: case report and review of the literature
title_short Cytokine release syndrome after radiation therapy: case report and review of the literature
title_sort cytokine release syndrome after radiation therapy case report and review of the literature
topic Cytokine release syndrome
Radiation therapy
Radiotherapy
Systemic inflammatory response syndrome
Cytokine
Tumor necrosis factor
url http://link.springer.com/article/10.1186/s40425-017-0311-9
work_keys_str_mv AT christopherabarker cytokinereleasesyndromeafterradiationtherapycasereportandreviewoftheliterature
AT samuelkkim cytokinereleasesyndromeafterradiationtherapycasereportandreviewoftheliterature
AT sadnabudhu cytokinereleasesyndromeafterradiationtherapycasereportandreviewoftheliterature
AT konstantinamatsoukas cytokinereleasesyndromeafterradiationtherapycasereportandreviewoftheliterature
AT anthonyfdaniyan cytokinereleasesyndromeafterradiationtherapycasereportandreviewoftheliterature
AT sandrapdangelo cytokinereleasesyndromeafterradiationtherapycasereportandreviewoftheliterature